Sentinel lymph node biopsy in patients with thin melanomas: Frequency and predictors of metastasis based on analysis of two large international cohortsShow others and affiliations
2018 (English)In: Journal of Surgical Oncology, ISSN 0022-4790, E-ISSN 1096-9098, Vol. 118, no 4, p. 599-605Article in journal (Refereed) Published
Abstract [en]
BackgroundSentinel lymph node (SLN) metastasis in patients with thin melanomas (1mm) is uncommon but adverse prognostic factors may indicate an increased risk. We sought to determine how often SLN biopsy (SLNB) was performed in patients with thin melanomas, establish the frequency of SLN metastasis and evaluate the predictive value of ulceration, tumor mitotic rate, and thickness for SLN involvement. MethodsMelanoma patients with a Breslow thicknessgreater than or equal to 0.5 to less than or equal to 1mm, diagnosed 2009-2016, were identified in the Swedish Melanoma Register (SMR) and the Melanoma Institute Australia (MIA) Database. ResultsIn total 8165 patients were included from the SMR and 1603 from MIA. SLNB was performed in 9.5% and 16.2% of patients, respectively. Corresponding figures for T1b (American Joint Committee on Cancer [AJCC] 7th Edition) were 19.5% and 24.6%. The SLN positivity rate were 4.4% (Sweden) and 5.8% (MIA). SLN metastasis was more frequent in tumors with ulceration, mitoses, and Breslow thickness greater than or equal to 0.9mm but none were statistically significant. Younger age was identified as a significant risk factor for SLN positivity at MIA. ConclusionsA minority of patients with thin melanomas had SLNB performed and the SLN positivity rate was low. This study did not confirm tumor ulceration, mitoses, or thickness as statistically significant predictors for SLN metastasis.
Place, publisher, year, edition, pages
WILEY , 2018. Vol. 118, no 4, p. 599-605
Keywords [en]
mitoses; sentinel lymph node biopsy; thickness; thin melanoma; ulceration
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:liu:diva-152404DOI: 10.1002/jso.25208ISI: 000446563500001PubMedID: 30196533OAI: oai:DiVA.org:liu-152404DiVA, id: diva2:1259605
Note
Funding Agencies|LMK foundation; Hudfonden; S.R. Gorthon foundation; Australian National Health and Medical Research Council; Swedish National Health Services; M. Paulsson Fund; S. Paulsson Fund
2018-10-302018-10-302018-10-30